Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biospecifics Tech Cp (NQ: BSTC )

88.53 USD UNCHANGED
Last Price Updated: 4:21 PM EST, Dec 1, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Biospecifics Tech Cp

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
BioSpecifics Technologies Corp. Reports Second Quarter 2016 Financial Results
-- Partner Endo exercised opt-in for human lipoma indication for CCH following positive Phase 2 results; triggers $750,000 opt-in payment to BioSpecifics -- 
From PR Newswire
BioSpecifics Technologies Corp. to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
10 Biotechnology Stocks to Sell Now
 
Tags NASDAQ:ADMA NASDAQ:ITEK NASDAQ:ANTH
From InvestorPlace
Biggest Movers in Manufacturing Stocks Now – BVXV STAA TKAI NBY
 
Tags NYSE:AXON NASDAQ:SCLN NASDAQ:AXSM
From InvestorPlace
BioSpecifics Technologies Reveals Positive Top-Line Results From Stage 2 Study Of CCH For Treatment of Human Lipoma
BioSpecifics Technologies Corp. (NASDAQ: BSTC) revealed Monday positive, statistically significant top-line results from its ... 
Tags Biotech Benzinga General
From Benzinga
BioSpecifics Technologies Reveals Positive Top-Line Results from Stage 2 Study Of CCH For Treatment of Human Lipoma
BioSpecifics Technologies Corp. (NASDAQ: BSTC) revealed Monday positive, statistically significant top-line results from its ... 
Tags News Benzinga ETFs
From Benzinga
BRIEF-Biospecifics Technologies positive results from phase 2 trial of CCH
* Biospecifics technologies corp. Announces positive top-line results from phase 2 trial of cch for treatment of human lipoma 
Tags companyNews
From Reuters: Company News
BioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma
- Trial meets primary endpoint of an 83.4% reduction in lipoma visible surface area relative to placebo - 
From PR Newswire
BioSpecifics Technologies Corp. to Present at the Jefferies 2016 Healthcare Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
The Implied Analyst 12-Month Target For PXSG
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
BioSpecifics Technologies Corp. Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
BioSpecifics Technologies Corp. to Present at the 2016 UBS Global Healthcare Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
BioSpecifics Technologies Corp. Reports First Quarter 2016 Financial Results
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
BioSpecifics Technologies Corp. to Report First Quarter 2016 Financial Results on Tuesday, May 10, 2016
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
The Math Shows PXSG Can Go To $28
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
BioSpecifics Technologies Corp. to Present at the 15th Annual Needham Healthcare Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed... 
From PR Newswire
BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2015 Financial Results
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product... 
From PR Newswire
Analysts Expect EES To Hit $86
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Benzinga's Top Initiations
Analysts at Barclays initiated coverage on Manitowoc Foodservice Inc (NYSE: MFS) with a Equal-weight rating. The target price for ... 
Tags FAST EXPE BSTC
From Benzinga
BioSpecifics Technologies Corp. to Present at the 28th Annual ROTH Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
BioSpecifics Technologies Corp. to Report Fourth Quarter and Full Year 2015 Financial Results on Monday, March 14, 2016
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed... 
From PR Newswire
Biospecifics Technologies Enters Oversold Territory (BSTC)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a... 
Tags Stocks
From Market News Video
Hottest Manufacturing Stocks Now – NYMX SLI ANTH SGI
 
Tags NASDAQ:TROV NASDAQ:ANTH Hot Stocks
From InvestorPlace
BioSpecifics Technologies Corp. to Present at the 2016 BIO CEO & Investor Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
BioSpecifics Technologies Corp. to Present at the Noble Financial Capital Markets' NobleCon12
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
Biggest Movers in Manufacturing Stocks Now – GSM EARS YECO EVGN
 
Tags NASDAQ:TBRA NASDAQ:GSM NASDAQ:EARS
From InvestorPlace
Hottest Manufacturing Stocks Now – EARS GSM SUNE EVGN
 
Tags NYSE:LDL NYSE:SUNE NASDAQ:AEGR
From InvestorPlace
Biggest Movers in Manufacturing Stocks Now – KBIO SRPT CXRX PULM
 
Tags NASDAQ:PETX NASDAQ:KLIC NASDAQ:GEOS
From InvestorPlace
BioSpecifics Technologies Corp. to Present at the Stifel 2015 Healthcare Conference
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed... 
From PR Newswire
Biggest Movers in Manufacturing Stocks Now – MITK ITEK IRIX TRIL
 
Tags Hot Stocks NASDAQ:NEOT NASDAQ:IMMU
From InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.